About Abraxis BioScience
Abraxis BioScience is a Healthcare company based in Chicago (United States) founded in 2005, and was acquired by Celgene in June 2010. Protein-based nanoparticle chemotherapeutics for cancer are developed. It operates in the Healthcare and Technology sectors. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its legal entity is ABRAXIS BIOSCIENCE, LLC. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Abraxis BioScience was founded in 2005 in Chicago, United States, within the biotechnology sector. Focus was placed on cancer therapeutics through the Nab Technology platform, which enables tumor-targeted delivery of anti-cancer drugs. A key product, Abraxane, a protein-based nanoparticle compound, was created for treating metastatic breast cancer and received FDA approval in 2005. Operations concluded with acquisition by Celgene in 2010.
- Headquarters Chicago, United States
- Stage Acquired
- SectorsHealthcareTechnology
- Website abraxisbio.com
- Social LinkedIn
- Acquired by Celgene (Jun 2010)
- Legal Name Abraxis Bioscience, Llc
Investors in Abraxis BioScience
Abraxis BioScience has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Celgene.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Therapies for cancer and inflammatory diseases are developed. | 1986 | celgene.com | Summit, United States |
Investor details for Abraxis BioScience
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Abraxis BioScience
2 dated milestones of Abraxis BioScience across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Abraxis BioScience is founded.
- Exit Acquired by Celgene.
Competitors of Abraxis BioScience
Abraxis BioScience has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Abraxis BioScience
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Abraxis BioScience (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Abraxis Bioscience
Complete news archive for Abraxis BioScience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Abraxis BioScience
Abraxis BioScience was founded in 2005.
Abraxis BioScience is headquartered in Chicago, United States. It is registered at Chicago, Illinois, United States.
Abraxis BioScience was founded in 2005 in Chicago, United States, within the biotechnology sector. Focus was placed on cancer therapeutics through the Nab Technology platform, which enables tumor-targeted delivery of anti-cancer drugs. A key product, Abraxane, a protein-based nanoparticle compound, was created for treating metastatic breast cancer and received FDA approval in 2005. Operations concluded with acquisition by Celgene in 2010.
Abraxis BioScience has 1 investor. Key investors include Celgene.
Abraxis BioScience operates through Abraxis Bioscience, Llc.
Yes. Abraxis BioScience was acquired by Celgene in June 2010.